Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis

Phase 2AC-101Positive

AI Analysis

Summary

Accro Bioscience announced the first patient dosing in a Phase IIb clinical trial of AC-101 for moderate-to-severe ulcerative colitis. The trial represents advancement in the company's development of novel therapeutics for immune-mediated diseases.

Clinical Trial Data

Phase

Phase IIb

Outcome Details

First patient dosed in Phase IIb study

Importance:5/10

Sentiment:

0.50

clinical-trialphase-2ulcerative-colitisimmunology

Related Companies

$BHIC $CHHE $TRAX

Read the original article

Published by PR Newswire Clinical Trials on September 20, 2026 10:00 AM

Read Original